1
Danny H Lewis: Controlled release of antiparasitic agents in animals. Alkermes Controlled Therapeutics II, Sterne Kessler Goldstein & Fox P L L C, March 31, 1998: US05733566 (390 worldwide citation)

A delivery system for providing antiparasitic agents to animals is provided and a method of treating parasitic infections in animals using such delivery systems is described. The delivery system is particularly useful for treatment with avermectins and milbemycins in lactide/glycolide polymeric matr ...


2
Edith Mathiowitz, Howard Bernstein, Eric Morrel, Kirsten Schwaller: Method for producing protein microspheres. Alkermes Controlled Therapeutics, Kilpatrick & Cody, December 21, 1993: US05271961 (244 worldwide citation)

Protein microspheres are formed by phase separation in a non-solvent followed by solvent removal. The preferred proteins are prolamines, such as zein, that are hydrophobic, biodegradable, and can be modified proteolytically or chemically to endow them with desirable properties, such as a selected de ...


3
Howard Bernstein, Eric Morrel, Edith Mathiowitz, Kirsten Schwaller, Thomas R Beck: Protein microspheres and methods of using them. Alkermes Controlled Therapeutics, Hamilton Brook Smith & Reynolds P C, October 21, 1997: US05679377 (183 worldwide citation)

Biodegradable, protein microspheres for in vivo release of a biologically active agent, as well as agricultural and environmental applications. The microspheres can be administered orally, intravenously, or subcutaneously for subsequent release. By selecting particular size ranges and the specific p ...


4
William M Pardridge, Paul R Schimmel: Chimeric peptides for neuropeptide delivery through the blood-brain barrier. Alkermes, Regents of University of California, Poms Smith Lande & Rose, February 20, 1990: US04902505 (165 worldwide citation)

Chimeric peptides adapted for delivering neuropharmaceutical agents, such as neuropeptides into the brain by receptor-mediated transcytosis through the blood-brain barrier. The chimeric peptides include a peptide which by itself is capable of crossing the blood-brain barrier by transcytosis at a rel ...


5
Phillip M Friden, Ruth M Starzyk, Sherie L Morrison, Eun Chung Park, John P McGrath: Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins. Alkermes, The Regents of the University of California, Hamilton Brook Smith & Reynolds P C, November 2, 1999: US05977307 (159 worldwide citation)

The present invention pertains to a method for delivering a neuropharmaceutical agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of a ligand-neuropharmaceutical agent fusion protein wherein the ligand is re ...


6
Mark A Tracy, John D Herberger, Paul A Burke, Paul F Herbert: Methods for fabricating polymer-based controlled release devices. Alkermes Controlled Therapeutics, Hamilton Brook Smith & Reynolds P C, November 23, 1999: US05989463 (156 worldwide citation)

The present invention relates to a polymer-based sustained release device, and methods of forming and using the device for the sustained release of an active agent. The improved method of the invention for forming a polymer-bases sustained release device comprises forming a polymer/active agent solu ...


7
Howard Bernstein, Yan Zhang, M Amin Khan, Mark A Tracy: Modulated release from biocompatible polymers. Alkermes Controlled Therapeutics Incorporated, Hamilton Brook Smith & Reynolds P C, August 12, 1997: US05656297 (151 worldwide citation)

The present invention relates to a composition for the modulated release of a biologically active agent. The composition comprises a biocompatible polymeric matrix, a biologically active agent which is dispersed within the polymeric matrix, and a metal cation component which is separately dispersed ...


8
Hye Jung Lee, OluFunmi L Johnson, Stephen E Zale, Mark A Tracy: Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent. Alkermes Controlled Therapeutics, Hamilton Brook Smith & Reynolds P C, June 29, 1999: US05916597 (145 worldwide citation)

Composition for the sustained release of a biologically active agent in vivo. The composition comprises microcarriers containing a first solid-phase biocompatible material and a biologically active agent, wherein said microcarriers sustain the in vivo release of the biologically active agent. The co ...


9
Howard Bernstein, Yan Zhang, M Amin Khan, Mark A Tracy: Modulated release from biocompatible polymers. Alkermes Controlled Therapeutics, Hamilton Brook Smith & Reynolds P C, June 15, 1999: US05912015 (132 worldwide citation)

The present invention relates to a composition for the modulated release of a biologically active agent. The composition comprises a biocompatible polymeric matrix, a biologically active agent which is dispersed within the polymeric matrix, and a metal cation component which is separately dispersed ...


10
Phillip M Friden, Ruth M Starzyk, Sherie L Morrison, Eun Chung Park: Transferrin neuropharmaceutical agent fusion protein. Alkermes, The Regents of the University of California, Hamilton Brook Smith & Reynolds P C, September 30, 1997: US05672683 (119 worldwide citation)

The present invention pertains to a method for delivering a neuropharmaceutical agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of a ligand-neuropharmaceutical agent fusion protein wherein the ligand is re ...